secwatch.observer — SEC 8-K summary
======================================

Issuer:     scPharmaceuticals Inc. (—)
CIK:        0001604950
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001193125-24-138214
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

scPharma Q1 net loss $14.1M; FUROSCIX revenue $6.1M, doses written up 28% QoQ
-----------------------------------------------------------------------------

- Net FUROSCIX revenue $6.1M vs $2.1M in Q1 2023; gross-to-net discount 19%.
- Net loss $14.1M vs $11.2M; cash and equivalents $58.4M at quarter end.
- 17,376 doses written (+28% QoQ); 8,074 filled (+15% QoQ); 2,938 in-services completed.
- Change Healthcare cyberattack estimated 10% negative impact on doses filled in Q1.
- FDA PDUFA date August 2024 for Class IV HF indication; PK study for auto-injector underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604950/000119312524138214/0001193125-24-138214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604950/000119312524138214/d810552d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-138214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer